CDNA vs CRNX
CareDx, Inc vs Crinetics Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
CRNX
Crinetics Pharmaceuticals, Inc.
69
Buy
| Metric | CDNA | CRNX |
|---|
| AI Score |
67
|
69
|
| Price |
$45.31
|
$84.69
|
| P/E Ratio |
21.06×
|
-16.77×
|
| ROE |
-7.0%
|
-46.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
70.6%
|
99.2%
|
| Debt / Equity |
0.05×
|
0.04×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
57.4
|
90.0
|
| Beta |
2.419
|
0.1302
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for CDNA versus CRNX.
CRNX leads by 2 points.
CRNX scores 69/100 (Buy) versus CDNA at 67/100 (Buy).
CDNA Committee View
83% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is bollinger bandwidth of 45.6% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 32.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 227.0% YoY — Growth
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical
CRNX Committee View
80% agreement
5 analysts
The primary driver is 3 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 90 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 90 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical